Answers are grounded in this paper and cite their sources.
This editorial refers to ‘Frailty trajectories after a cardiovascular event among community-dwelling older people’, by A. Z. Z. Phyo, et al., https://doi:10.1093/eurjpc/zwaf095. Frailty and cardiovascular disease (CVD) are closely linked, particularly in older adults, influencing each other in ways that require careful attention in clinical practice. Which comes first? Does frailty accelerate cardiovascular decline, or do cardiovascular events (CVEs) trigger frailty progression? More than just coexisting conditions, frailty and CVD appear to reinforce each other, shaping long-term health trajectories. Defined by reduced physiological reserve and increased vulnerability to stressors, frailty is no longer a concept confined to geriatric medicine—it is now recognized as a key factor across all domains of cardiology.1 Frailty is now well established as a prognostic marker in CVD, particularly heart failure. Notably, recent major therapeutic trials are increasingly factoring in frailty status, acknowledging its role in refining clinical decision-making.2 However, important questions remain: Can cardiovascular interventions slow frailty progression? Could targeting frailty improve cardiac outcomes? Longitudinal studies like that of Phyo et al. provide valuable insights into these issues.3 The study, ‘Frailty trajectories after a cardiovascular event among community-dwelling older people,’ by Phyo et al. provides crucial insights into how CVEs shape frailty trajectories.3 This landmark study followed 19 111 community-dwelling older adults over a median of 8.3 years, all initially free of CVD. Frailty was assessed annually using two complementary tools: the Frailty Index (FI), measuring 64 deficits across physical, cognitive, and social domains, and the Fried phenotype, which evaluates physical frailty through metrics like grip strength and walking speed. Their findings reveal a clear pattern: frailty increases significantly following CVEs, particularly stroke, myocardial infarction (MI), and hospitalization for heart failure (HHF). Stroke and HHF had the most pronounced short-term impact, which may reflect their higher inflammatory burden, prolonged recovery times, and effects on mobility. While the Fried phenotype captured short-term physical declines, the FI revealed sustained frailty progression, increasing by an average of 3.65 points immediately after a CVE and continuing to worsen over time. These results suggest that CVEs do more than temporarily weaken patients—they may accelerate a broader, long-term accumulation of deficits. By focusing on a community-dwelling population, this study expands our understanding beyond hospital-based research. It highlights that frailty is also a concern for individuals living independently. Certain subgroups appeared particularly vulnerable, including women, individuals over 80 years, those living alone, and patients with polypharmacy. These findings reinforce the need to consider frailty in a broader socio-medical context, where biological, social, and environmental determinants all play a role. The relationship between frailty and CVD runs both ways: while CVEs accelerate frailty, frailty itself is a strong predictor of future cardiovascular events.1 Studies show that frail individuals are at higher risk of developing CVD. Frailty has been associated with a nearly threefold increased risk of stroke, coronary heart disease, and peripheral vascular disease, and an almost ninefold risk of heart failure compared to robust individuals.4 These findings suggest that frailty is not just a marker of biological aging but an active contributor to cardiovascular vulnerability. One possible explanation lies in inflammaging—the chronic, low-grade inflammation that accompanies aging. Growing evidence suggests that shared inflammatory pathways between frailty and CVD, particularly in heart failure, may underpin their strong and interdependent association.5 Phyo et al.’s findings highlight the value of assessing frailty alongside cardiac function after CVEs, offering crucial insights into patient vulnerability and shaping long-term recovery strategies. However, standardizing frailty assessment in cardiology remains a challenge. The FI is highly sensitive for tracking long-term frailty progression but may not be practical for routine clinical use. Simpler tools, such as the FRAIL Scale or Clinical Frailty Scale (CFS), offer quick, practical alternatives, feasible for non-specialists and paramedics.1 FRAIL Scale offers a concise, five-item questionnaire evaluating fatigue, resistance, ambulation, illnesses, and weight loss. Similarly, the Clinical Frailty Scale (CFS) uses a visual scoring system ranging from 1 (very fit) to 9 (terminally ill), enabling quick and reliable evaluations in acute care settings Haut du formulaireBas du formulaire. In heart failure patients, a multi-domain frailty assessment model has recently been proposed by the Heart Failure Association of the European Society of Cardiology (HFA-ESC), integrating clinical, functional, psycho-cognitive, and social domains.6 These tools effortlessly integrate into clinical workflows, making comprehensive frailty assessment more accessible. When frailty is not identified and managed early, its impact extends beyond an individual patient’s prognosis. At the patient level, frailty is associated with higher morbidity and mortality, increased hospitalizations, prolonged recovery times, and greater dependence on caregivers. Without timely intervention, frailty can accelerate functional decline, limiting treatment options and leading to poorer cardiovascular outcomes.1,7 For clinicians, frailty presents a different challenge. Frail patients are often excluded from clinical trials, which means that many therapeutic decisions are based on extrapolated data rather than robust evidence. This gap in research contributes to uncertainty in treatment strategies, making it difficult to establish clear, evidence-based guidelines for managing CVD in frail populations. As a result, therapeutic decisions may potentially lead to undertreatment or overly conservative management approaches. Moving beyond this reactive approach requires integrating frailty into routine cardiovascular care—not just as a risk factor to be accounted for, but as a modifiable condition. Recognizing frailty is an important step, but managing it effectively is what truly impacts patient outcomes. Cardiac rehabilitation (CR) remains a key tool for improving frailty-related outcomes. However, frail patients are often underrepresented in the study programmes, despite being the group likely to benefit the most.8 Managing frailty in CVD requires a multidimensional approach that addresses physical, nutritional, and psychosocial domains, ensuring that interventions are as comprehensive as the challenges frailty presents.1 To address this, frailty-adapted CR programmes could help make rehabilitation more accessible and effective. Evidence highlights that CR programmes with frailty-specific interventions can lead to substantial improvements in outcomes, including reduced hospitalization and mortality risks.1,9,10 Key interventions include resistance exercises to restore muscle strength, nutritional support to counteract malnutrition, and cognitive training to enhance mental resilience. Beyond structured rehabilitation, sodium-glucose linked transporter (SGLT)-2 inhibitors may offer more than just cardiovascular protection—emerging evidence suggests they also improve geriatric outcomes, including cognitive function, functional status, and aging-related biomarkers, expanding their potential role in older patients with diabetes and heart failure.11 Optimizing these broader effects requires close collaboration between cardiologists and geriatricians, whose complementary expertise ensures a balanced approach between cardiovascular protection and frailty management. Supported by a multidisciplinary team, including rehabilitation specialists, nutritionists, and social support services, this synergy allows for more tailored interventions that address both cardiac health and geriatric complexity in frail older patients. Finally, beyond rehabilitation, the concept of ‘prehabilitation’ is gaining traction as a transformative approach to managing frail cardiac patients. This strategy focuses on enhancing patients’ functional capacity and resilience prior to major cardiac interventions. Such proactive measures are especially relevant for frail individuals who face heightened risks of postoperative complications. By preparing patients for the physiological demands of surgery or intervention, prehabilitation offers a pathway to better outcomes and recovery. Frailty is not just a consequence of cardiovascular disease—it actively influences both risk and recovery. The study by Phyo et al. reinforces how CVEs accelerate frailty progression, underscoring the need to incorporate frailty assessment into routine cardiovascular care. Recognizing frailty as a dynamic, modifiable condition rather than an inevitable aspect of aging shifts the focus towards early intervention and personalized management strategies. A.A. drafted the manuscript. M.G. and A.B. critically revised the manuscript. All authors gave final approval and agreed to be accountable for all aspects of the work ensuring integrity and accuracy. The authors received no financial support for the research, authorship, and/or publication of this article. No new data were generated or analysed in support of this research.
No takes yet. Share an insight, caveat, or question.
Aïdoud et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: